Lixte Inventory vs Short Long Term Debt Total Analysis

LIXTW Stock

USD 0.03 0.01 21.74%

Lixte Biotechnology financial indicator trend analysis is infinitely more than just investigating Lixte Biotechnology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lixte Biotechnology is a good investment. Please check the relationship between Lixte Biotechnology Inventory and its Short Long Term Debt Total accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Inventory vs Short Long Term Debt Total

Inventory vs Short Long Term Debt Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lixte Biotechnology Inventory account and Short Long Term Debt Total. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Lixte Biotechnology's Inventory and Short Long Term Debt Total is -0.14. Overlapping area represents the amount of variation of Inventory that can explain the historical movement of Short Long Term Debt Total in the same time period over historical financial statements of Lixte Biotechnology Holdings, assuming nothing else is changed. The correlation between historical values of Lixte Biotechnology's Inventory and Short Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Inventory of Lixte Biotechnology Holdings are associated (or correlated) with its Short Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt Total has no effect on the direction of Inventory i.e., Lixte Biotechnology's Inventory and Short Long Term Debt Total go up and down completely randomly.

Correlation Coefficient

-0.14

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Inventory

Short Long Term Debt Total

Most indicators from Lixte Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lixte Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

At this time, Lixte Biotechnology's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 3.9 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 3.02 in 2024.

	2023	2024 (projected)
Interest Income	20.5K	12.4K
Gross Profit	180K	160K

Interest Income Gross Profit

Lixte Biotechnology fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant And Equipment Net	Accounts Payable	Non Current Assets Total	Other Current Assets	Property Plant And Equipment Gross	Short Long Term Debt Total	Short Term Debt	Short Term Investments	Net Receivables	Inventory	Current Deferred Revenue	Capital Surpluse
Total Assets		0.65	0.24	0.96	-0.97	-0.76	0.95	0.96	0.73	-0.28	0.76	0.24	1.0	-0.3	-0.32	0.46	0.81	-0.34	-0.32	-0.11	0.91	-0.11	-0.66	0.4	0.35	0.92
Other Current Liab	0.65		0.46	0.63	-0.63	-0.72	0.63	0.64	0.54	0.03	0.7	0.46	0.65	-0.19	-0.3	0.41	0.68	-0.5	-0.3	-0.23	0.75	0.18	-0.47	0.42	0.72	0.7
Total Current Liabilities	0.24	0.46		0.21	-0.22	-0.45	0.22	0.23	0.26	0.18	0.43	1.0	0.24	0.13	-0.79	0.66	0.33	-0.21	-0.79	-0.12	0.25	0.33	-0.01	0.71	0.48	0.22
Total Stockholder Equity	0.96	0.63	0.21		-1.0	-0.84	1.0	1.0	0.83	-0.31	0.86	0.21	0.96	-0.4	-0.3	0.42	0.8	-0.38	-0.3	-0.35	0.88	-0.14	-0.71	0.32	0.34	0.92
Net Debt	-0.97	-0.63	-0.22	-1.0		0.83	-1.0	-1.0	-0.81	0.31	-0.85	-0.22	-0.97	0.38	0.3	-0.43	-0.79	0.42	0.3	0.32	-0.89	0.17	0.72	-0.33	-0.34	-0.92
Retained Earnings	-0.76	-0.72	-0.45	-0.84	0.83		-0.84	-0.84	-0.86	0.35	-0.99	-0.45	-0.75	0.38	0.48	-0.51	-0.73	0.28	0.48	0.59	-0.72	0.08	0.71	-0.55	-0.69	-0.87
Cash	0.95	0.63	0.22	1.0	-1.0	-0.84		1.0	0.82	-0.31	0.86	0.22	0.95	-0.39	-0.3	0.43	0.79	-0.43	-0.3	-0.36	0.88	-0.17	-0.72	0.32	0.33	0.92
Cash And Short Term Investments	0.96	0.64	0.23	1.0	-1.0	-0.84	1.0		0.83	-0.28	0.86	0.23	0.96	-0.4	-0.31	0.44	0.79	-0.42	-0.31	-0.36	0.88	-0.13	-0.71	0.33	0.33	0.92
Common Stock Total Equity	0.73	0.54	0.26	0.83	-0.81	-0.86	0.82	0.83		-0.2	0.89	0.26	0.73	-0.77	-0.2	0.31	0.86	-0.34	-0.2	-0.6	0.77	-0.08	-0.56	0.29	0.48	0.86
Common Stock Shares Outstanding	-0.28	0.03	0.18	-0.31	0.31	0.35	-0.31	-0.28	-0.2		-0.33	0.18	-0.28	-0.01	0.01	0.04	-0.18	-0.2	0.01	0.1	-0.1	0.78	0.37	-0.03	-0.31	-0.26
Other Stockholder Equity	0.76	0.7	0.43	0.86	-0.85	-0.99	0.86	0.86	0.89	-0.33		0.43	0.76	-0.44	-0.46	0.46	0.75	-0.31	-0.46	-0.64	0.74	-0.08	-0.68	0.51	0.65	0.87
Total Liab	0.24	0.46	1.0	0.21	-0.22	-0.45	0.22	0.23	0.26	0.18	0.43		0.24	0.13	-0.79	0.66	0.33	-0.21	-0.79	-0.12	0.25	0.33	-0.01	0.71	0.48	0.22
Total Current Assets	1.0	0.65	0.24	0.96	-0.97	-0.75	0.95	0.96	0.73	-0.28	0.76	0.24		-0.29	-0.32	0.46	0.81	-0.34	-0.32	-0.1	0.91	-0.11	-0.66	0.39	0.34	0.91
Common Stock	-0.3	-0.19	0.13	-0.4	0.38	0.38	-0.39	-0.4	-0.77	-0.01	-0.44	0.13	-0.29		-0.35	0.16	-0.62	0.32	-0.35	0.51	-0.45	0.12	0.18	0.19	-0.21	-0.49
Property Plant And Equipment Net	-0.32	-0.3	-0.79	-0.3	0.3	0.48	-0.3	-0.31	-0.2	0.01	-0.46	-0.79	-0.32	-0.35		-0.55	-0.17	-0.1	1.0	0.12	-0.22	-0.27	0.11	-0.87	-0.29	-0.25
Accounts Payable	0.46	0.41	0.66	0.42	-0.43	-0.51	0.43	0.44	0.31	0.04	0.46	0.66	0.46	0.16	-0.55		0.4	-0.13	-0.55	0.0	0.29	0.31	-0.54	0.44	0.29	0.39
Non Current Assets Total	0.81	0.68	0.33	0.8	-0.79	-0.73	0.79	0.79	0.86	-0.18	0.75	0.33	0.81	-0.62	-0.17	0.4		-0.38	-0.17	-0.18	0.83	-0.06	-0.51	0.23	0.51	0.82
Other Current Assets	-0.34	-0.5	-0.21	-0.38	0.42	0.28	-0.43	-0.42	-0.34	-0.2	-0.31	-0.21	-0.34	0.32	-0.1	-0.13	-0.38		-0.1	0.27	-0.49	0.17	0.27	0.03	-0.09	-0.38
Property Plant And Equipment Gross	-0.32	-0.3	-0.79	-0.3	0.3	0.48	-0.3	-0.31	-0.2	0.01	-0.46	-0.79	-0.32	-0.35	1.0	-0.55	-0.17	-0.1		0.12	-0.22	-0.27	0.11	-0.87	-0.29	-0.25
Short Long Term Debt Total	-0.11	-0.23	-0.12	-0.35	0.32	0.59	-0.36	-0.36	-0.6	0.1	-0.64	-0.12	-0.1	0.51	0.12	0.0	-0.18	0.27	0.12		-0.18	0.08	0.3	-0.14	-0.3	-0.35
Short Term Debt	0.91	0.75	0.25	0.88	-0.89	-0.72	0.88	0.88	0.77	-0.1	0.74	0.25	0.91	-0.45	-0.22	0.29	0.83	-0.49	-0.22	-0.18		-0.08	-0.53	0.33	0.47	0.9
Short Term Investments	-0.11	0.18	0.33	-0.14	0.17	0.08	-0.17	-0.13	-0.08	0.78	-0.08	0.33	-0.11	0.12	-0.27	0.31	-0.06	0.17	-0.27	0.08	-0.08		0.17	0.22	-0.06	-0.08
Net Receivables	-0.66	-0.47	-0.01	-0.71	0.72	0.71	-0.72	-0.71	-0.56	0.37	-0.68	-0.01	-0.66	0.18	0.11	-0.54	-0.51	0.27	0.11	0.3	-0.53	0.17		-0.16	-0.3	-0.72
Inventory	0.4	0.42	0.71	0.32	-0.33	-0.55	0.32	0.33	0.29	-0.03	0.51	0.71	0.39	0.19	-0.87	0.44	0.23	0.03	-0.87	-0.14	0.33	0.22	-0.16		0.46	0.43
Current Deferred Revenue	0.35	0.72	0.48	0.34	-0.34	-0.69	0.33	0.33	0.48	-0.31	0.65	0.48	0.34	-0.21	-0.29	0.29	0.51	-0.09	-0.29	-0.3	0.47	-0.06	-0.3	0.46		0.51
Capital Surpluse	0.92	0.7	0.22	0.92	-0.92	-0.87	0.92	0.92	0.86	-0.26	0.87	0.22	0.91	-0.49	-0.25	0.39	0.82	-0.38	-0.25	-0.35	0.9	-0.08	-0.72	0.43	0.51

Click cells to compare fundamentals

Lixte Biotechnology Account Relationship Matchups

Lixte Biotechnology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.7M	5.2M	5.1M	5.6M	4.3M	2.2M
Other Current Liab	237.9K	10.5K	302.9K	394.8K	313.9K	171.6K
Total Current Liabilities	237.9K	216.5K	302.9K	394.8K	313.9K	290.7K
Total Stockholder Equity	2.4M	5.0M	4.8M	5.2M	4.0M	4.2M
Net Debt	(2.6M)	(5.1M)	(4.8M)	(5.4M)	(4.2M)	(4.0M)
Retained Earnings	(27.1M)	(30.4M)	(37.1M)	(43.4M)	(48.5M)	(46.1M)
Cash	2.6M	5.1M	4.8M	5.4M	4.2M	4.4M
Cash And Short Term Investments	2.6M	5.1M	4.8M	5.4M	4.2M	4.4M
Common Stock Shares Outstanding	1.1M	1.1M	1.3M	158.2K	1.9M	1.8M
Liabilities And Stockholders Equity	2.7M	5.2M	5.1M	5.6M	4.3M	2.2M
Other Stockholder Equity	26.0M	31.9M	38.4M	45.1M	49.0M	51.4M
Total Liab	237.9K	216.5K	302.9K	394.8K	313.9K	290.7K
Total Current Assets	2.7M	5.2M	5.1M	5.6M	4.2M	2.2M
Accounts Payable	143.5K	190.3K	226.0K	229.8K	156.8K	169.4K
Other Current Assets	58.8K	159.2K	10.2K	10.4K	27.1K	25.8K
Short Term Debt	210.9K	237.9K	302.9K	394.8K	313.9K	193.4K
Current Deferred Revenue	94.3K	15.8K	77.0K	165.0K	157.1K	81.5K
Capital Surpluse	20.0M	25.3M	26.0M	31.9M	36.6M	26.5M
Net Invested Capital	(1.1M)	1.5M	1.3M	1.7M	494.8K	317K
Net Working Capital	2.4M	5.0M	4.8M	5.2M	4.0M	4.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lixte Inventory vs Short Long Term Debt Total Analysis

Inventory vs Short Long Term Debt Total

Inventory vs Short Long Term Debt Total Correlation Analysis

Correlation Coefficient

Inventory

Short Long Term Debt Total

Lixte Biotechnology fundamental ratios Correlations

Lixte Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lixte Biotechnology fundamental ratios Accounts

Also Currently Popular

Additional Tools for Lixte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Cash	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Stockholder Equity
Other Stockholder Equity	- 0.99	Retained Earnings
Total Current Assets	- 0.97	Net Debt
Net Debt	- 0.97	Total Assets